Name Fred Hassan | Role Executive | |
 | ||
Education Harvard Business School (1972), Imperial College London (1967), University of London | ||
2013 young partners pharma executive summit fred hassan fireside chat
Fred Hassan (born November 12, 1945, in Multan, Pakistan) is a managing director at Warburg Pincus, which he joined in 2011. He was the Chairman of the Board and Chief Executive Officer of pharmaceutical company Schering-Plough from 2003 until November 3, 2009, when the company completed its merger with Merck & Co. Hassan was the Chairman of the Board of Bausch & Lomb from March 2010 until its sale in 2013. On October 29, 2009, Time Warner announced that Hassan would join their Board of Directors.
Contents
- 2013 young partners pharma executive summit fred hassan fireside chat
- Fred hassan talks about leadership and his new book reinvent with valerie bowling
- Education
- Business career
- References
Fred hassan talks about leadership and his new book reinvent with valerie bowling
Education
Hassan earned a degree in chemical engineering from the Imperial College London in 1967, and an M.B.A. from Harvard Business School in 1972.
Business career
Hassan began his career with Sandoz Pharmaceuticals, where he spent 17 years and ended up leading its U.S. pharmaceuticals business. He then became executive vice president of Wyeth, responsible for its pharmaceutical and medical products divisions, and was elected to the Board of Directors in 1995. Hassan joined Pharmacia & Upjohn in May 1997 as chief executive officer and in February 2001 he was named Chairman of the Board of Pharmacia after the merger with Monsanto Company. He has also served as Chairman of the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) and for the HealthCare Institute of New Jersey. Hassan is also the current president of the International Federation of Pharmaceutical Manufacturers Associations and serves on the Board of Directors of Avon Products, Inc. In 2009, Hassan was listed 6th on the Forbes.com rankings for CEO compensation in the drugs and biotechnology industry.